Cargando…

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

INTRODUCTION: To evaluate the possibility that switching from reference biologic medicines to biosimilars could lead to altered clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy for patients, a systematic literature review was conducted of all switching...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Hillel P., Blauvelt, Andrew, Rifkin, Robert M., Danese, Silvio, Gokhale, Sameer B., Woollett, Gillian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854749/ https://www.ncbi.nlm.nih.gov/pubmed/29500555 http://dx.doi.org/10.1007/s40265-018-0881-y

Ejemplares similares

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Cohen, Hillel P., et al.
Publicado: (2018)

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

A ‘Global Reference’ Comparator for Biosimilar Development
por: Webster, Christopher J., et al.
Publicado: (2017)

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
por: Cohen, Hillel P., et al.
Publicado: (2023)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Worldwide experience with biosimilar development
por: McCamish, Mark, et al.
Publicado: (2011)

An Efficient Development Paradigm for Biosimilars
por: Webster, Christopher J., et al.
Publicado: (2019)

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”
por: Webster, Christopher J., et al.
Publicado: (2019)

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
por: Webster, Christopher J., et al.
Publicado: (2018)

Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
por: McKinnon, Ross A., et al.
Publicado: (2018)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

The Importance of Countering Biosimilar Disparagement and Misinformation
por: Cohen, Hillel P., et al.
Publicado: (2020)

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch
por: Sagi, Sreedhar, et al.
Publicado: (2023)

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis
por: Herndon, Thomas M., et al.
Publicado: (2023)

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2017)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Clinical trials for authorized biosimilars in the European Union: a systematic review
por: Mielke, Johanna, et al.
Publicado: (2016)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
por: Triantafyllidi, Eleni, et al.
Publicado: (2022)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

The Role of PD Biomarkers in Biosimilar Development – To Get the Right Answer One Must First Ask the Right Question
por: Woollett, Gillian R., et al.
Publicado: (2022)

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
por: Magalhaes, Diogo, et al.
Publicado: (2023)

Comment on Hernandez-Vasquez et al., a bibliometric analysis of the global research on biosimilars
por: Cohen, Hillel P.
Publicado: (2018)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
por: Ascef, Bruna O., et al.
Publicado: (2021)

The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies
por: Odinet, Johlee S., et al.
Publicado: (2018)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?
por: McCamish, M, et al.
Publicado: (2013)

Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics
por: Panda, Sunita, et al.
Publicado: (2023)

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics
por: Limdi, Jimmy K, et al.
Publicado: (2021)

Safety of pancreatic surgery with special reference to antithrombotic therapy: A systematic review of the literature
por: Fujikawa, Takahisa, et al.
Publicado: (2021)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
por: Liu, Yifei, et al.
Publicado: (2019)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review
por: Puzzono, Marta, et al.
Publicado: (2021)

Systematic review—pancreatic involvement in inflammatory bowel disease
por: Massironi, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9l2nnd02nn0t7a8hue9nqbsrre